Handbook of Psychopharmacology
없습니다
도서+교보Only(교보배송)을 함께 15,000원 이상 구매 시 무료배송
15,000원 미만 시 2,500원 배송비 부과
20,000원 미만 시 2,500원 배송비 부과
15,000원 미만 시 2,500원 배송비 부과
1Box 기준 : 도서 10권
알립니다.
- 본 상품은 주문 후 제작되는 맞춤도서입니다.
주문기간에 따라 도서 출고일은 영업일 기준 최소 3일에서 최대 8일이 소요됩니다. - 해외주문도서는 고객님의 요청에 의해 주문하는 '개인 오더' 상품이기 때문에, 단순한 고객변심/착오로 인한 취소, 반품, 교환의 경우 '해외주문 반품/취소 수수료'를 부담하셔야 합니다. 이점 유의하여 주시기 바랍니다.
- 반품/취소 수수료:(1)서양도서-판매정가의 12%, (2)일본도서-판매정가의 7% (반품/취소 수수료는, 수입제반비용(FedEx수송비용, 관세사비, 보세창고료, 내륙 운송비, 통관비 등)과 재고리스크(미판매 리스크, 환차손)에 따른 비용을 포함하며, 서양도서는 판매정가의 12%, 일본도서는 판매정가의 7%가 적용됩니다.)
- 외국도서의 경우 해외제공정보로만 서비스되어 미표기가된 정보가 있을 수 있습니다. 필요한 정보가 있을경우 1:1 문의게시판 을 이용하여 주십시오.
취소/반품에 대한 안내
POD도서는 고객 주문 후 제작되는 도서로, 단순변심 및 착오로 인한 취소, 반품이 절대 불가하니 이점 반드시 유의하여 주시기 바랍니다.
해외주문/바로드림/제휴사주문/업체배송건의 경우 1+1 증정상품이 발송되지 않습니다.
패키지
북카드
목차
- 1 Neuropathological and Neurochemical Aspects of Alzheimer?s Disease.- 1. Introduction.- 2. The Neuropathology of Alzheimer?s Disease.- 2.1. The Gross Changes of Alzheimer?s Disease.- 2.2. Nerve Cell Loss in Alzheimer?s Disease.- 2.3. Degenerative Changes in Nerve Cells in Alzheimer?s Disease.- 2.4. The Senile Plaque.- 2.5. The Neurofibrillary Tangle.- 2.6. Granulovacuolar Degeneration.- 2.7. The Hirano Body.- 2.8. Lewy Bodies and Alzheimer?s Disease.- 2.9. Changes in Glial Cells.- 2.10. Changes in Blood Vessels.- 2.11. The Relationship between Senile Plaques, Neurofibrillary Tangles, and Cerebrovascular Amyloid.- 3. Alzheimer-Type Changes in Conditions Other than Alzheimer?s Disease.- 3.1. Nondemented Individuals of All Ages.- 3.2. Down?s Syndrome at Middle Age.- 3.3. Parkinson?s Disease.- 3.4. Boxer?s Encephalopathy and Other Conditions.- 4. Alzheimer?s Disease and Patient Age.- 5. Biochemical Correlates of Pathological Changes.- 5.1. Neurotransmitter Changes.- 5.2. Changes in Protein Synthesis.- 6. Relationship between Plaques and Tangles and Nerve Cell Atrophy and Loss.- 7. Relationship between Extent of Pathological Changes and Degree of Dementia.- 7.1. Gross and Light Microscopic Relationships.- 7.2. Relationships to Dementia at Ultrastructural Level.- 8. Pathogenetic Considerations.- 8.1. Where Is the Site of the Primary Lesion in Alzheimer?s Disease? Is It in the Cerebral Cortex or in the Subcortex?.- 8.2. Is the SP or the NFT the Site of Primary Damage to Nerve Cells in Alzheimer?s Disease?.- 8.3. How Are SP Formed?.- 8.4. Where Does the Process of Alzheimer?s Disease Begin?.- 9. Concluding Remarks.- 10. References.- 2 Basal Forebrain Cholinergic Neurons and Alzheimer?s Disease.- 1. Introduction.- 2. Basal Forebrain Cholinergic Systems.- 3. Cholinergic Alterations in AD.- 3.1. Cortex.- 3.2. Basal Forebrain.- 3.3. Cerebral Spinal Fluid AChE and Other Peripheral Changes.- 4. Cholinergic Physiology.- 4.1. Behavioral Experiments.- 4.2. Electrophysiological Studies.- 4.3. Transsynaptic Consequences of Basal Forebrain Cholinergic Lesions in Experimental Animals.- 4.4. Cholinergic Pharmacotherapy in AD.- 5. Conclusion.- 6. References.- 3 Neurochemical Studies in Dementia.- 1. Introduction.- 1.1. Definition of Dementia.- 1.2. Methodology of Human Neurochemistry.- 2. Alzheimer?s Disease.- 2.1. Acetylcholine.- 2.2. Correlations of Cholinergic Deficit with Cognitive Impairment.- 2.3. Norepinephrine and Dopamine.- 2.4. Serotonin.- 2.5. Amino Acids.- 2.6. Neuropeptides.- 3. Other Cortical Dementias.- 4. Subcortical Dementias.- 4.1. Parkinson?s Disease and Progressive Supranuclear Palsy.- 4.2. Huntington?s Disease.- 4.3. Depression.- 5. Alcohol Dementia.- 6. Confusional States.- 7. Summary.- 8. References.- 4 Chemical Neuroanatomy of Alzheimer?s Disease.- 1. Introduction: Relationship of Neural Connections and Neurotransmitters with Alzheimer Pathology.- 2. Limbic and Cortical Connections and Neurotransmitters in Alzheimer?s Disease.- 2.1. Distribution of Lesions in the Hippocampal Formation.- 2.2. Distribution of Lesions in the Amygdala.- 2.3. Distribution of Neocortical Lesions.- 2.4. Neurotransmitters in Affected Limbic and Corticocortical Connections.- 3. Brain Stem and Basal Forebrain-Cortical Connections and Neurotransmitters in Alzheimer?s Disease.- 3.1. Magnocellular Basal Nucleus.- 3.2. Thalamic Intralaminar Nuclei.- 3.3. Hypothalamus.- 3.4. Brain Stem Monoamine Cell Groups.- 3.5. Brain Stem Cholinergic Cell Groups.- 4. Implications for the Pathogenesis and Treatment of Alzheimer?s Disease.- 5. References.- 5 Dementia in Parkinson?s Disease.- 1. Introduction.- 2. Brain Lesions in Patients with Parkinson?s Disease.- 3. Dementia and Lesions.- 3.1. Neuropathology.- 3.2. Neurochemistry.- 4. Parkinsonian Dementia.- 4.1. Prevalence.- 4.2. Characteristics of Parkinsonian Psychopathology.- 5. Symptoms and Lesions.- 5.1. Dopamine-Dependent Symptoms?.- 5.2. Norepinephrine-Dependent Symptoms?.- 5.3. Serotonin-Dependent Symptoms?.- 5.4. Acetylcholine-Dependent Symptoms?.- 5.5. Somatostatin-Dependent Symptoms?.- 6. Conclusion.- 7. References.- 6 Alzheimer?s Disease: Genetic Theories of Etiology.- 1. Introduction.- 2. The Genetic Hypothesis.- 2.1. Pedigree Studies of Presenile Disease.- 2.2. Studies of Pooled Proband Relatives.- 3. Critical Methodological Issues.- 3.1. Diagnostic Heterogeneity.- 3.2. Age-Dependent Onset.- 3.3. Resulting Ambiguity in Classical Twin and Linkage Studies.- 4. Predicted Characteristics of Genetically Caused AD.- 4.1. Gene Expression May Be Described by a Probability Distribution.- 4.2. Expected Familial Incidence in a Rare Dominant Disorder.- 4.3. Expected Familial Incidence When a Dominant Predisposing Gene Is Common.- 4.4. Effect of Gene Frequency on Relative Risks for Proband versus Control Relatives.- 4.5. Effects of Phenocopies in the Index Case Series.- 5. Review of Previous Studies.- 5.1. Approach.- 5.2. Studies before 1955.- 5.3. Studies after 1955.- 6. Current Studies.- 6.1. The Minnesota State Hospital Studies.- 6.2. The Duke Collaborative Studies.- 6.3. The Baltimore Nursing Home Study.- 6.4. The New York Studies.- 6.5. Autosomal Dominant Inheritance Suggested by Both the Baltimore and New York Studies.- 7. Implications and Strategies for Future Research.- 7.1. Status of the Genetic Hypothesis.- 7.2. Implications of Age-Dependent Expression of AD.- 7.3. Additional Research Strategies.- 8. References.- 7 The Cholinergic Hypothesis of Memory: A Review of Animal Experiments.- 1. Introduction.- 2. Conceptual Issues.- 3. Methodological Issues.- 4. Anatomy of Forebrain Cholinergic Pathways.- 5. Pharmacology of Central Cholinergic Neurons.- 6. Pharmacological Evidence for Cholinergic Involvement in Sensory, Attentional, and Motor Functions.- 7. Pharmacological Studies of Rodent Learning and Memory.- 7.1. Discrimination Learning.- 7.2. Avoidance Learning.- 7.3. Spontaneous and Rewarded Alternation Behavior.- 7.4. Maze Learning.- 7.5. Intracerebral Injections.- 8. Lesion Studies.- 8.1. Lesions of Ascending Cholinergic Projections.- 8.2. Recovery of Function after Lesions.- 8.3. Tissue Transplants.- 9. Pharmacological Studies of Primate Memory.- 9.1. Delayed Matching to Sample.- 9.2. Primate Studies: Delayed Responding.- 9.3. Other Behavioral Tasks.- 9.4. Primate Studies: Conclusions.- 10. Summary and Concluding Remarks.- 11. References.- 8 Behavioral Models of Aging in Nonhuman Primates.- 1. Introduction.- 2. Some Characteristics of Age-Related Behavioral Deficits in Nonhuman Primates.- 2.1. Behavioral Test Paradigms.- 2.2. Recent Memory Impairment.- 2.3. Hypersensitivity to Visual Interference.- 2.4. Discrimination Learning.- 2.5. Impairment in Reversal Learning.- 2.6. Synopsis.- 3. Relationship of Age-Related Behavioral Deficits in Nonhuman Primates to Humans.- 3.1. Impairments in Recent Memory.- 3.2. Hypersensitivity to Interfering Stimuli.- 3.3. Increased Perseveration/Behavioral Rigidity.- 3.4. Development of Human Memory Tests Based on Nonhuman Primate Tasks.- 4. Relationship of Age-Related Behavioral Deficits in Nonhuman Primates to Rodents.- 4.1. Recent Memory.- 4.2. Hypersensitivity to Interference.- 4.3. Increased Perseveration/Behavioral Rigidity.- 4.4. Summary.- 5. Possible Insights from Comparisons with Nonhuman Primates Given Discrete Brain Lesions.- 5.1. Frontal Cortex Lesions.- 5.2. Nucleus Basalis of Meynert Lesions.- 5.3. Hippocampal Lesions.- 5.4. Amygdala Lesions.- 5.5. Combined Lesions of Different Brain Regions.- 5.6. Summary.- 6. Possible Insights from Drugs That Impair Performance on Memory Tasks in Young Subjects.- 6.1. Scopolamine and Other Anticholinergics.- 6.2. Diazepam and Benzodiazepines.- 6.3. Tetrahydrocannabinol.- 7. Drugs for Improving Age-Related Cognitive Losses: Current Status and Future Prospects.- 7.1. Neurotransmitter Modulation.- 7.2. Nootropics.- 7.3. Neuropeptides.- 8. Synthesis and Discussion.- 9. References.- 9 Cholinergic Drugs and Human Cognitive Performance.- 1. Introduction.- 2. The Effects of Cholinergic Agents on Processes Involved in Learning and Memory in Experimental Animals.- 3. The Effects of Cholinergic Agents on Processes Involved in Learning and Memory in Young Adult Human Subjects.- 4. Clinical Trials of Cholinergic Agents in Patients with Dementia of the Alzheimer Type or Aged Volunteers.- 5. Implications and New Directions.- 6. References.- 10 Treatment of Dementia with Vasoactive Drugs.- 1. Background and Rationale.- 1.1. Multiinfarct Dementia.- 1.2. Degenerative Dementias.- 2. Traditional Vasodilators.- 3. Recent Developments and Future Prospects.- 3.1. Calcium Channel Blockers.- 3.2. Excitatory Amino Acid Antagonists.- 4. References.- 11 New Pharmacological Perspectives on Nootropic Drugs.- 1. Introduction.- 2. Known Compounds.- 3. Goals of This Chapter.- 4. Distribution of Drugs in Brain.- 5. Neuropsychopharmacological Studies.- 5.1. Aged Rat Quantitative EEG.- 5.2. Therapeutic Window Discovered in Quantitative EEG Studies.- 5.3. Effects on New Learning and the Therapeutic Window.- 5.4. Effects on Firing Rate of Neurons of the Medial Septal Nucleus and the Area Ventral to the Globus Pallidus.- 5.5. Therapeutic Window Shown in Single-Neuron Firing Rate.- 5.6. Cerebral Intraventricular Administration of Pramiracetam and Piracetam and Effects on Single-Neuron Firing Rates.- 5.7. Functional Hippocampal Lesions and the Therapeutic Window.- 6. Neurochemical Studies.- 7. Relationship to Endogenous Substances.- 8. Nootropic Drugs and Arguments for Supplementary Choline.- 9. Clues to the Mode of Action of Nootropic Drugs.- 10. Some Thoughts on Clinical Trials.- 11. Summary and Conclusion.- 12. References.
기본정보
ISBN | 9781461282525 ( 1461282527 ) |
---|---|
발행(출시)일자 | 2011년 09월 26일 |
쪽수 | 500쪽 |
크기 |
170 * 244
* 26
mm
/ 794 g
|
총권수 | 1권 |
언어 | 영어 |
Klover
e교환권은 적립 일로부터 180일 동안 사용 가능합니다.
리워드는 작성 후 다음 날 제공되며, 발송 전 작성 시 발송 완료 후 익일 제공됩니다.
리워드는 리뷰 종류별로 구매한 아이디당 한 상품에 최초 1회 작성 건들에 대해서만 제공됩니다.
판매가 1,000원 미만 도서의 경우 리워드 지급 대상에서 제외됩니다.
일부 타인의 권리를 침해하거나 불편을 끼치는 것을 방지하기 위해 아래에 해당하는 Klover 리뷰는 별도의 통보 없이 삭제될 수 있습니다.
- 도서나 타인에 대해 근거 없이 비방을 하거나 타인의 명예를 훼손할 수 있는 리뷰
- 도서와 무관한 내용의 리뷰
- 인신공격이나 욕설, 비속어, 혐오발언이 개재된 리뷰
- 의성어나 의태어 등 내용의 의미가 없는 리뷰
리뷰는 1인이 중복으로 작성하실 수는 있지만, 평점계산은 가장 최근에 남긴 1건의 리뷰만 반영됩니다.
구매 후 리뷰 작성 시, e교환권 200원 적립
문장수집
e교환권은 적립 일로부터 180일 동안 사용 가능합니다. 리워드는 작성 후 다음 날 제공되며, 발송 전 작성 시 발송 완료 후 익일 제공됩니다.
리워드는 한 상품에 최초 1회만 제공됩니다.
주문취소/반품/절판/품절 시 리워드 대상에서 제외됩니다.
구매 후 리뷰 작성 시, e교환권 100원 적립